Phase 1/2 clinical results: CBP-1018 for heavily pre treated mCRPC patients, promising!
A new clinical trial shows CBP-1018, an experimental bi-ligand–drug conjugate, could be a promising treatment for mCRPC, as presented at ASCO GU 2025.
Among 76 patients treated at effective doses, 88% had disease control, 20% had significant tumor shrinkage, and 60% saw tumor size reduction.
At seven
A new clinical trial shows CBP-1018, an experimental bi-ligand–drug conjugate, could be a promising treatment for mCRPC, as presented at ASCO GU 2025.
Among 76 patients treated at effective doses, 88% had disease control, 20% had significant tumor shrinkage, and 60% saw tumor size reduction.
At seven